Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL publishes this guide as part of THE BALANCE GROUP. Its residence is in Mallorca, Spain. We compare selected US medical and addiction services with the possibility of a suitable residential stay abroad; we do not imply that COGNIFUL has a US campus. The comparison is publisher-authored and is not an independent ranking of equivalent luxury facilities. [1]

The word prescription does not establish safety, and dependence does not automatically establish addiction. A person can take a benzodiazepine as directed and develop physical dependence without a substance use disorder. Another person may struggle with impaired control, escalating use and continued harm. The joint benzodiazepine guideline explicitly distinguishes these patterns because they affect treatment decisions. [2]

Bring the actual medicine list, not only the most recent electronic record. Include product names, formulations, prescribed instructions, actual use, alcohol, supplements and medication obtained from other sources. Identify every relevant prescriber. A clear timeline helps a clinician see whether symptoms followed a medication change, a change in use, worsening pain or another event. Do not resolve conflicting instructions on your own.

An assessment should also protect legitimate treatment needs. Pain, insomnia, anxiety or attention-related difficulties may still need care even if medication use has become harmful. Ask how those needs will be addressed alongside addiction treatment. A universal requirement to stop every prescription does not demonstrate an individualized clinical plan.

Hazelden Betty Ford’s Center City program describes medically managed detox and stabilization, residential and outpatient care, and opioid-related treatment. Hanley Center describes onsite medical detox in West Palm Beach. These services are included for their stated clinical roles, not as proof that either accepts every complex prescription case or offers the same residential format as COGNIFUL. Verify the specific program, current availability and medical exclusions. [3] [4]

For a person considering Spain, the comparison must include the extra handover. A US treatment plan may involve a primary-care clinician, specialist, pharmacy and insurer. Those arrangements do not automatically continue through an overseas residence. The responsible professionals should agree the proposed medication and follow-up pathway before travel becomes the deciding factor.

When prescription opioids are involved, ask whether opioid use disorder has been diagnosed and how pain will be treated. The CDC recommends medication treatment for opioid use disorder and advises against detoxification alone because of increased risks of return to use, overdose and overdose death. Detox completion should not be treated as the entire recovery plan. [6]

Ask the provider how appropriate medication is offered or arranged, who will continue it and what overdose-prevention education is included. If a residential program relies on outside clinicians, those relationships need to be concrete. A promise to find someone later is weaker than an accepting provider and an appointment. Do not stop effective treatment solely to meet a program’s assumed preference for medication-free care.

For someone with chronic pain, request a plan that addresses function as well as medication risk. What activities are difficult? Which treatments have helped? What happens during pain flares? The answer should not force a choice between acknowledging pain and acknowledging a problematic pattern of use. These concerns can be assessed together while the appropriate medical specialists retain responsibility.

Benzodiazepines can cause serious withdrawal when stopped abruptly or reduced too rapidly, including seizures. Their combination with opioids or alcohol can also be dangerous. The FDA warning calls for an individual plan, not an instruction to stop on the day a residential place becomes available. Tell the assessing clinician about previous withdrawal reactions and every sedating product used. [7]

The joint guideline recognizes that some medication changes require an extended period of care. Ask how the program will manage the transition if the prescriber-led plan continues after a stay. Medical withdrawal care and therapy for a harmful pattern of use can be connected, but they are not identical services. A fixed residential package should not determine the pace of a medical process. [2]

If sleep medication is central to the concern, the proposal should include an insomnia assessment and an appropriate longer-term sleep plan. CBT-I is a usual first treatment for chronic insomnia in NHLBI guidance. Ask whether a qualified professional provides it or whether referral is needed. A private suite and relaxation activities may support comfort but do not establish specialist insomnia treatment. [8]

Stimulant concerns require assessment of the original indication, current use, sleep, physical symptoms and mental state. ASAM and AAAP guidance treats stimulant intoxication and withdrawal as specific clinical issues. A general drug-detox package does not by itself show the necessary medical and psychiatric capability. Ask how the proposed setting fits the actual presentation. [9]

Antidepressant withdrawal should not automatically be labeled addiction. Some medication concerns mainly need careful prescribing review and continuing treatment of the original illness. COGNIFUL’s medication page states these distinctions and recommends understanding the exact drug and its purpose. A provider that can recommend outpatient care when sufficient is giving useful information, even when the person initially asks for rehab. [1]

Request an explanation of what treatment would change beyond the medication list. Goals might involve coping with distress, reducing secrecy, communicating with clinicians, responding to cravings or rebuilding ordinary routines. They should arise from the person’s history. A list of therapy names or a standard daily schedule does not show how the program understands the prescription concern.

Family participation should have a defined purpose and consent boundaries. Relatives may help describe changes in functioning, but they should not become the decision makers for medication adjustments. If a family member pays, clarify what financial information they receive and what clinical information remains private. The person in care should have space to describe pain, fear, shame or uncertainty without needing to manage everyone else’s reaction.

COGNIFUL provides residential care in Mallorca for people whose needs are suitable for its setting. Prescription-medication concerns are assessed in context, including dependence, addiction, current stability and other medical or psychiatric needs. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Clinical assessment determines the appropriate care plan and setting. In some cases, treatment may begin with an initial 1–3 days in a partner hospital for observation and stabilization before continuing at COGNIFUL. The pathway is planned around each person’s medical needs. Appropriate medical care may need to occur before a stay can be considered. [1] [10]

The residence accommodates no more than four clients at any time, with a private suite for each person. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, excursions and activities are shared. This is a specific small-residence model; it does not establish exclusive accommodation, a one-client team, a fixed staffing ratio or superior recovery results. [5]

For a US resident, the proposal should explain how treatment remains connected to the clinicians at home. Who will review prescriptions during the stay? Which services are available onsite, which require external care, and what happens if the medical situation changes? Any essential specialist involvement must be confirmed. A broad description of individualized therapy does not guarantee a particular method or prescribing capability. [10]

COGNIFUL Premier and Premier Plus both include assessment, a personal treatment plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is agreed individually. The typical four-to-twelve-week stay is reviewed for the person and is not a promised medication-withdrawal timeline. [5] View program fees

US families should request a written total in euros, with duration, inclusions, external costs and payment terms. COGNIFUL generally operates as self-pay and does not bill insurers directly. It may provide documentation for a reimbursement request, but coverage or payment is not guaranteed. Domestic and overseas quotations should be compared on the same scope rather than on headline prices alone.

Before departure, identify an accepting US clinician for continuing prescriptions and other follow-up. Clarify what COGNIFUL’s aftercare will actually provide from Spain and what must occur locally. Do not assume universal US telehealth access or cross-border prescribing. The transition plan should be practical for the person’s state of residence, time zone, work and family life. [11]

• Has the assessment distinguished physical dependence from a substance use disorder?
• How are pain, anxiety, insomnia or other original treatment needs being addressed?
• What medical service manages any withdrawal, and who has accepted responsibility?
• For opioid use disorder, how is evidence-based medication treatment provided and continued?
• Which post-discharge appointments are booked, and which services remain to be arranged?

Take unanswered questions back to the relevant clinical professional. A polished admissions experience does not resolve a gap in prescribing or emergency capability. Conversely, an honest explanation that another level of care is needed can be a sign of a more useful assessment. The decision should leave the client and family able to describe the full pathway in clear terms.

Does a prescription make addiction unlikely enough to ignore?

No. A legitimate prescription and a harmful pattern can coexist. Equally, dependence alone does not establish addiction. Assessment should consider actual use, control, consequences and medical needs rather than rely on either assumption. [2]

Is detox alone enough for prescription opioid addiction?

For opioid use disorder, the CDC advises against detoxification alone and recommends medication treatment. A complete plan should connect appropriate medical treatment with ongoing support and overdose prevention. Ask exactly who will provide that care. [6]

Is there a COGNIFUL facility in the US?

The verified COGNIFUL residence is in Mallorca, Spain. US residents can inquire about suitability, but this requires a clear plan for travel, prescribing responsibilities and follow-up at home. [5]

Should I discontinue medication before admission?

Do not independently change prescriptions to prepare for a program. Abrupt benzodiazepine withdrawal can be dangerous. The responsible clinician should guide any change and determine whether medical care is required before residential treatment. [7]

COGNIFUL admissions can explain the Mallorca programs and the information needed for clinical review. Share the exact prescription concern, relevant US clinicians and any withdrawal or overdose history. The goal is an appropriate medical and residential pathway with clear responsibilities from the beginning. [5]

1. Prescription medication concerns and residential treatment — COGNIFUL.
2. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
3. Addiction and mental health services in Center City — Hazelden Betty Ford Foundation.
4. Medical services and detox — Hanley Center.
5. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
6. Opioid use disorder: treating — Centers for Disease Control and Prevention.
7. Benzodiazepine safety communication — US Food and Drug Administration.
8. Insomnia treatment — National Heart, Lung, and Blood Institute.
9. Clinical Practice Guideline on the Management of Stimulant Use Disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry.
10. Clinical scope, suitability and care coordination — COGNIFUL.
11. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.